Welcome to the e-CCO Library!

P399: Vedolizumab therapy results in reduced hospitalisation and steroid use over 1-year: Results from the Scottish vedolizumab consortium
Year: 2018
Source: ECCO '18 Vienna
Authors:

N. Plevris1*, C.S. Chuah1, R. Allen2, P. Baker2, P. Brennan3, A. Churchhouse1, E. Donoghue4, D. Gaya2, H. Jafferbhoy5, P. Jenkinson1, G. Jones1, J. Macdonald2, M. MacMaster2, C. Mowat3, G. Naismith6, L. Potts7, E. Saffouri2, J.P. Seenan2, A. Sengupta5, P. Shasi3, J. Todd3, J. Veryan2, A. Watson8, D. Watts4, I. Arnott1, C. Lees1, M. Groome3 M. Calvo1*, I. Alonso2, K. Villa1,3, V. Matallana1, Y. González Lama1, M.I. Vera1, A. Sanchez Movilla2, P. Calvo2, A. Royuela4, L. Abreu1

Created: Thursday, 21 February 2019, 9:14 AM
P400 Understanding the impact of TNF-α antagonists on the severity of non-melanoma skin cancer in inflammatory bowel disease and the consequences for therapy
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Townsend, R. Khanna, A.S. Wilson

Created: Thursday, 30 January 2020, 10:12 AM
P400: Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the Swiss IBD Cohort Study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

T. Greuter*1, L. Biedermann1, G. Rogler1, E. Safroneeva2, A. Schoepfer3, S. Vavricka1, 4

Created: Friday, 22 February 2019, 9:49 AM
P400: Bowel ultrasonography, a non invasive easy-to-use method to predict the need to step-up therapy in inflammatory bowel disease patients
Year: 2021
Source: ECCO'21 Virtual
Authors: Les, A.(1);Iacob, R.(1);Cotruta, B.(1);Saizu, R.(1);Gheorghe, L.(1);Gheorghe, C.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P400: Discordance in patient and physician perspectives and priorities in communication and management of ulcerative colitis: results of the European ulcerative colitis narrative survey
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

L. Peyrin-Biroulet1, A. Hart2, C. Kayhan3, A. Armuzzi4, S. Schreiber*5

Created: Friday, 22 February 2019, 9:41 AM
P400: Evolution of clinical and pharmacological parameters after switching from intra-venous to subcutaneous infliximab in patients with inflammatory bowel disease: the REMSWITCH study
Year: 2022
Source: ECCO'22
Authors: Buisson, A.(1);Nachury, M.(2);Reymond, M.(1);Yzet, C.(3);Wils, P.(2);Payen, L.(1);Manlay, L.(1);Pereira, B.(4);Fumery, M.(3);
Created: Friday, 11 February 2022, 3:52 PM
P400: Identifying Nutritional targets in Crohn's disease: INTICO1: a time-limited trial of exclusive enteral nutrition during adult CD remission
Year: 2023
Source: ECCO’23 Copenhagen
Authors: McDonnell, M.(1,2)*;Westoby, C.(3);Sartain , S.(1);Giannasca, P.(4);Corthésy, J.(5);Grzywinski, Y.(6);Frézal, A.(5);Capt, P.(5);Cummings, F.(1);Wootton, S.(7);
Created: Friday, 14 July 2023, 11:05 AM
P400: Risk-adjusted use of thiopurines prevented surgical recurrence in patients with Crohn's disease after intestinal resection
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Guo J.1, Mao R.1, Luo X.1, Ben Horin S.1,2, Chen M.*3

Created: Wednesday, 20 February 2019, 10:36 AM
P401 Sarcopenia in children and young adults with primary sclerosing cholangitis and IBD
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E. Shteyer1, R. Cytter-Kuint2, L. Winberg2

Created: Thursday, 30 January 2020, 10:12 AM
P401: Anti-TNF treatments in Crohn's disease and improvement in work productivity and quality of life: an observational study from Turkey
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Törüner M.*1, Başaranoğlu M.2, Atuğ Ö.3, Şentürk Ö.4, Akyüz F.5, Ünsal B.6, Över Hamzaoğlu H.7, Tekin F.8, Sezgin O.9, Akpınar H.10, Çelik A.F.11, Tezel A.12, Göktürk H.S.13, Kav T.14

Created: Wednesday, 20 February 2019, 10:36 AM
P401: Association between induction vedolizumab drug levels and therapy outcome in inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. O'Connell1, M. S. Ismail2, M. McCormack3, P. McDonagh1, R. Argue4, N. Breslin2,5, V. Crowley3, G. Cullen5,6, G. A. Doherty5,6, C. Dunne1,5, K. Hartery1,5, F. MacCarthy5,7, S. McKiernan1,5, H. Mulcahy5,6, A. O'Connor2,5, C. O'Morain8, B. Ryan2,5, J. Sheridan5,6, M. Healy3, D. McNamara2,5, D. Kevans1,5

Created: Friday, 22 February 2019, 9:41 AM
P401: Concomitant azathioprine treatment effects vedolizumab treatment persistence in Crohn's Disease but not in Ulcerative Colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Toruner, M.(1)*;Guvenir, T.(1);Er, R.E.(1);Soykan, I.(1);
Created: Friday, 14 July 2023, 11:05 AM
P401: Confocal laser endomicroscopy predicts response in patients with acute inflammatory bowel disease undergoing anti-integrin therapy with vedolizumab
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Ellrichmann*1, J. Bethge1, G. Aust1, A. Arlt1, B. Brandt1, S. Zeissig1, 2, S. Nikolaus1, K. Aden1, S. Schreiber1

Created: Friday, 22 February 2019, 9:49 AM
P401: Reduction of dosing intervals is the preferable dose optimisation strategy for infliximab to suppress formation of anti-drug antibodies
Year: 2018
Source: ECCO '18 Vienna
Authors:

W. Reinisch1*, A. Eser1, S. Schreiber2, H. Kim3, D. Mould4

Created: Thursday, 21 February 2019, 9:14 AM
P401: Risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications: Reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study
Year: 2021
Source: ECCO'21 Virtual
Authors: Lamb, C.A.(1,2);Sebastian, S.(3,4);Kent, A.J.(5);Segal, J.P.(6);Gonzalez, H.A.(3,4);Brookes, M.J.(7,8);Mehta, S.J.(9);Subramanian, S.(10,11);Bhala, N.(12,13);Hicks, L.C.(6);Conley, T.E.(10);Patel, K.V.(14);Walker, G.J.(15);Kennedy, N.A.(16,17);
Created: Wednesday, 2 June 2021, 4:12 PM
P401: Tofacitinib tissue exposure correlates with endoscopic outcome
Year: 2022
Source: ECCO'22
Authors: Verstockt., B.(1,2);Alsoud, D.(2);van Oostrom, J.(3);Smith, J.(4);Stylli, J.(4);Singh, S.(4);van Gennep, S.(3);Rahimian, P.(4);Sabino, J.(1,2);Ferrante, M.(1,2);Singh, S.(4);D'Haens, G.(1);Vermeire, S.(1,2);
Created: Friday, 11 February 2022, 3:52 PM
P402 Prediction of emergency department re-visit among Crohn’s disease patients: a retrospective study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

H. Mahajna1, Y. Barash2, B. Ungar1, S. Soffer2, S. Ben-Horin1, E. Klang2, U. Kopylov1

Created: Thursday, 30 January 2020, 10:12 AM
P402: A novel high-dose mesalazine tablet is as effective as conventional low-dose mesalazine tablets in inducing remission in patients with mildly to moderately active ulcerative colitis (UC): A double-blind, double-dummy, multicentre, randomised trial
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Dignaß*1, R. Schnabel2, J. Romatowski3, V. Pavlenko4, A. Dorofeyev5, J. Derova6, L. Jonaitis7, T. Nacak8, R. Greinwald8

Created: Friday, 22 February 2019, 9:49 AM
P402: A Pilot Study on the Effect of Colesevelam on the Microbiome in Primary Terminal Ileal Resected Crohn's Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kumar, A.(1)*;Quraishi, M.N.(2);Al-Hassi, H.O.(3);Elasrag, M.(4);Segal, J.P.(5);Jain, M.(1);Steed, H.(1);Butterworth, J.(6);Farmer, A.(7);McLaughlin, J.(8);Beggs, A.(4);Brookes, M.(1);
Created: Friday, 14 July 2023, 11:05 AM
P402: Discontinuation of short-term infliximab maintenance therapy in patients with Crohn's disease: outcomes and risk factors associated with relapse
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Zheng D.1, Mao R.1, Chen B.1, Feng T.1, Ben-Horin S.2, Chen M.*1

Created: Wednesday, 20 February 2019, 10:36 AM